Journal of Developmental Origins of Health and Disease

www.cambridge.org/doh

Original Article

Cite this article: Dorot A, Wainstock T, Sheiner E, Walfisch A, Landau D, and Harlev A. (2020) Isolated oligohydramnios and long-term neurological morbidity of the offspring. Journal of Developmental Origins of Health and Disease **11**: 648–652. https://doi.org/10.1017/ S2040174419000795

Received: 2 June 2019 Revised: 21 September 2019 Accepted: 14 October 2019 First published online: 22 November 2019

Keywords:

idiopathic oligohydramnios; decreased amniotic fluid; long-term outcome; movement disorders; developmental disorders; fetal development

Address for correspondence:

Avi Harlev, Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Email: Harlev@bgu.ac.il

[†]The first two authors contributed equally to the manuscript.

© Cambridge University Press and the International Society for Developmental Origins of Health and Disease 2019.



Isolated oligohydramnios and long-term neurological morbidity of the offspring

Avital Dorot^{1,†}, Tamar Wainstock^{2,†}, Eyal Sheiner³, Asnat Walfisch³, Daniella Landau⁴ and Avi Harlev³

¹Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; ²Department of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; ³Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel and ⁴Department of Neonatology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Abstract

This study aimed to assess the association between maternal-isolated oligohydramnios (IO) and offspring long-term neurological complications. A population-based retrospective cohort study was conducted, including all births at a single tertiary medical center in Israel between the years 1991 and 2014. Multiple pregnancies and potential pregnancy complications associated with oligohydramnios were excluded. The computerized obstetrical database was linked with the computerized dataset of all pediatric hospitalizations of the same medical center. Evaluation of cumulative neurological-associated hospitalizations rate over time was compared using a Kaplan-Meier survival curve. The Weibull survival parametric model was conducted to assess the neurological-associated hospitalization risk in the presence of IO, while accounting for potential confounders. A total of 190,259 pregnancies were included in the study, of which 4063 (2.13%) pregnancies were complicated with IO. Total neurological-related hospitalizations were significantly more common in the IO group (3.7% in the IO group and 3.0% in the comparison group, p = 0.005). Pervasive developmental disorder, movement disorders, developmental disorders, and degenerative and demyelization disorders were all specific neurological diagnoses significantly more common in the exposed group. The survival curve demonstrated a significantly higher cumulative hospitalization rate in the exposed group (log-rank p = 0.001). Using a multivariate model adjusting for gestational age, maternal age, and labor induction, an independent association between IO and long-term neurological morbidity of the offspring was observed (adjusted hazard ratio 1.203; 95% CI 1.02-1.42). In summary, a significant association was found between pregnancies complicated by IO and long-term neurological morbidity of the offspring.

Introduction

Oligohydramnios or decreased amniotic fluid volume (AFV) occurs in approximately 0.5%–5% of pregnancies.¹ Several etiologies may cause oligohydramnios including fetal causes (e.g., genitourinary anomalies), placental causes (e.g., placental insufficiency),² maternal causes (e.g., hypertensive disease and renal disease), pharmacological agents (e.g., angiotensin-converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs),^{3–6} and premature rupture of membranes (PROM).^{7–9} Isolated oligohydramnios (IO) also known as idiopathic oligohydramnios accounts for less than half of the oligohydramnios cases^{8,10} and is believed to arise from decreased placental perfusion and hypoxemia, leading to a diminished generation of fetal urine.¹¹

While some studies reported that IO is not associated with adverse perinatal outcomes,¹²⁻¹⁴ other studies suggest differently. Previously reported perinatal complications associated with oligohydramnios include meconium-stained amniotic fluid, low Apgar scores, admissions to neonatal intensive care unit, congenital malformations, and even neonatal death.^{15,16} Increased rates of labor induction and cesarean deliveries were also shown to be associated with IO.^{17,18}

However, little has been reported regarding long-term outcomes in children born after pregnancies complicated by IO, especially when assessed as an independent variable. Long-term complications of IO were previously reported by Chien *et al.*¹⁹, in which an increased risk of respiratory-related hospitalizations was suggested in IO exposed offspring. In addition, an increased risk for cerebral palsy (CP) or even death at 18 months was described by Sasahara *et al.*,²⁰ though, unlike our study, this study was designed for preterm small for gestational age infants born with oligohydramnios. Unfortunately, no validated evidence regarding a possible association between IO and long-term neurological morbidity of the offspring was found. This study was constructed due to the high index of suspicion based on these reports as well as the overall limited evidence implying short- and long-term complications, and based on the notion in which an inappropriate environment for the fetus may project on its well-being and development,^{21–23} thus drafted in search of evidence for long-term offspring neurological morbidity in pregnancies complicated with IO.

Methods and materials

A population-based retrospective cohort study approved by the Institutional Review Board, including all births that occurred between the years 1991 and 2014 at a tertiary university medical center ("Soroka" - SUMC) was conducted. SUMC is the single tertiary and birth center in the region, with a computerized database which includes data on all deliveries that occurred at the facility since 1991, including pregnancy follow-up and newborn information. Although these data were collected prospectively, it is analyzed as a retrospective design. All deliveries occurring in SUMC are documented by the in-charge obstetrician and later validated by designated medical secretaries. For the current study, data were retrieved from the obstetric computerized database combined with the pediatric hospitalization dataset. The pediatric dataset contains all emergency room (ER) visits and hospitalizations up to 18 years of age. Neurological-related hospitalizations of offspring were compared between the IO exposed group and all other pregnancies ("unexposed"). Pregnancy complications that are associated with oligohydramnios were excluded: multiple pregnancies, any type of diabetes mellitus, intrauterine growth restriction, pregnancy-related hypertensive disorders, congenital malformations, placental abruption, RH-isoimmunizations, and PROM, as well as polyhydramnios. Thus, the IO group contains idiopathic cases only without multiple pregnancy complications cases. All neurological diagnoses received during any hospitalization of all offspring up to 18 years of age were included in the analysis. These were classified using the international classification ICD-9 system (as shown in Supplementary Table S1).

All pediatric ER visits and hospitalizations are documented in the patient's medical record. Diagnosis of all offspring morbidities mentioned in any pediatric medical records was collected and stratified by system into several main categories, including all neurological morbidities. These morbidities are defined according to the ICD-9 (as shown in Supplementary Table S1). All neurological diagnoses received during any hospitalization of all offspring up to 18 years of age were included in the analysis.

Follow-up time was defined as the time between the date of birth and the first neurological-related hospitalization or until censored. Censoring occurred in case of death (during hospitalization, other than neurological-related) or at age 18 (which was calculated for each child based on date of birth). Only the first hospitalization for each child was included in the analyses.

Background maternal characteristics included age at delivery, parity, and gravidity. The index pregnancy and obstetrical covariates included gestational age upon delivery, preterm delivery (defined as occurring before 37 weeks of gestation and before 34 weeks of gestation), and labor induction. The perinatal covariates analyzed included fetal gender, birthweight, low birthweight (<2500 g), macrosomia (>4000 g), and low Apgar score at 1 and 5 min (<7).

Since SUMC is the only tertiary medical center in the Negev region (south of Israel) which serves all the Negev residents, the study population was nonselective.

Statistical analysis

Since this was a retrospective cohort study, the "exposed" offspring were compared to the "unexposed" offspring. All offspring with IO were defined as exposed, and all offspring without this diagnosis served as the comparison group. The dependent variable was considered a first hospitalization with neurological diagnosis (event), while the independent variable was the presence or absence of oligohydramnios (exposed vs. unexposed).

Univariable analysis was performed to compare dependent and background characteristics between the two study groups. Cumulative incidence rates were compared using a Kaplan–Meier survival curve, and the log-rank test was used to determine significant differences. The Weibull survival parametric model (which adjusted for maternal multiple occurrences within the database, i.e., sibling) was conducted to compare neurological-associated hospitalizations risk by status of oligohydramnios (yes/no). The model adjusted for potential confounders based on the univariable analysis and on clinical relevance. The final model was chosen based on best fit and minimal –2log likelihood.

Results

During the study period, 190,259 singleton deliveries met the inclusion criteria, of which 2.13% (n = 4063) were complicated with IO and composed the exposed group. The number of neurological-related hospitalizations of offspring up to the age of 18 years, for both the exposed and unexposed pregnancies, was 5655 (2.97%).

Table 1 presents the background characteristics of the study groups. Primiparity was more common in the IO group, while maternal age did not significantly differ between the study groups. The IO group also demonstrated a higher rate of labor induction (62.6% vs. 21.2% in the unexposed group, p < 0.001) and infants in the IO group exhibited lower mean birthweight as compared to normal AFV (3107 and 3240 g, p < 0.001).

Table 2 details selected long-term neurological diagnoses of the offspring according to the presence or absence of IO. The study groups demonstrated a significant difference in total neurological-related hospitalizations (3.7% in the IO group and 3.0% in the comparison group, p = 0.005). Specific neurological diagnoses found to be more common in the exposed group included pervasive developmental disorder (PDD), movement disorders, developmental disorders, and degenerative and demyelization disorders.

Fig. 1 depicts the cumulative hazard for any neurological hospitalization of the offspring, accounting for hospitalizations occurring within the child's first 18 years of age. A higher cumulative hospitalization incidence rate was demonstrated in the IO group as compared with the unexposed group (log-rank, p = 0.001).

Table 3 presents the results of the Weibull multivariable analysis evaluating the association between AFV and neurological-associated hospitalization risk, while adjusting for gestational age (in weeks), maternal age, and induction of labor. Exposed offspring were 1.203 (95% CI 1.022–1.417) more likely to be hospitalized due to a neurological cause as compared with their unexposed counterparts.

Table 1. Characteristics of the study groups

Characteristics n (%)		Pregnancies complicated by isolated oligohydramnios n = 4063	Pregnancies with normal AFV n = 186,196	p	
Maternal characteristics					
Maternal age, years (mean ± SD)		27.88 ± 5.627	27.85 ± 5.672	0.687	
	1	1199 (29.5)	33,482 (18)		
Gravidity	2-4	1794 (44.2)	92,299 (49.6)	<0.001	
	5+	1070 (26.3)	60,394 (32.4)		
	1	1471 (36.2)	39,778 (21.4)		
Parity	2-4	1802 (44.4)	98,969 (53.2)	<0.001	
	5+	788 (19.4)	47,426 (25.5)		
Pregnancy and delivery fac	ctors				
Gestational age, weeks (mean \pm SD)		39.56 ± 1.767	39.31 ± 1.609	<0.001	
Preterm delivery (<37 wee	ks)	202 (5)	8758 (4.7)	0.433	
Preterm delivery (<34 wee	ks)	32 (0.8)	1158 (0.6)	0.187	
Labor induction		2528 (62.2)	39,428 (21.2)	<0.001	
Neonatal factors					
	Male	2091 (51.5)	94,340 (50.7)	0.318	
Gender	Female	1972 (48.5)	91,856 (49.3)		
Birthweight, grams (mean	± SD)	3107.94 ± 462.141	3240.95 ± 451.092	<0.001	
Very low birthweight < 150	Very low birthweight < 1500 g		243 (0.1)	0.001	
Low birthweight < 2500 g		293 (7.2)	7815 (4.2)	<0.001	
Birthweight > 4000 g (macr	osomia)	105 (2.6)	8242 (4.4)	<0.001	
Apgar score < 7 at 1 min		202 (5)	8536 (4.6)	0.24	
Apgar score < 7 at 5 min		28 (0.7)	3816 (2)	<0.001	

AFV, amniotic fluid volume; SD, standard deviation.

All numbers in table represent n (%) except where otherwise mentioned.

Table 2. The association between amniotic fluid volume (isolated oligohydramnios vs. normal) and offspring long-term neurological morbidity

	Isolated oligohydramnios	Normal			
Offspring long-term morbidity	n (%)	AFV n (%)	RR	95% CI	<i>p</i> -value
PDD	2 (<0.1)	13 (<0.1)	7.053	1.591-31.266	0.04
Eating disorders	6 (0.1)	313 (0.2)	0.878	0.391-1.971	0.753
Sleep disorders	2 (<0.1)	30 (<0.1)	3.056	0.73-12.792	0.149
Movement disorders	95 (2.3)	3292 (1.8)	1.33	1.082-1.635	0.007
СР	4 (0.1)	142 (0.1)	1.291	0.478-3.489	0.558
Psychiatric emotional	19 (0.5)	875 (0.5)	0.995	0.631-1.569	0.986
ADHD	1 (<0.1)	100 (0.1)	0.458	0.064-3.285	0.728
Developmental disorders	8 (0.2)	151 (0.1)	2.431	1.193-4.953	0.022
Degenerative disorders, demyelization	8 (0.2)	123 (0.1)	2.985	1.459-6.106	0.007
Headache	1 (<0.1)	44 (<0.1)	1.042	0.143-7.561	0.621
Myopathy	2 (<0.1)	106 (0.1)	0.865	0.213-3.504	0.42
Other	21 (0.5)	676 (0.4)	1.426	0.923-2.204	0.114
Total neurologic hospitalization	151 (3.7)	5504 (3)	1.267	1.075-1.494	0.005

AFV, amniotic fluid volume; RR, relative risk; CI, confidence interval; PDD, pervasive developmental disorder; CP, cerebral palsy; ADHD, attention-deficit hyperactivity disorder.

 Table 3. Multivariate analysis for prediction of offspring long-term neurologic

 morbidity

Variable	Adj. HR	95% CI	<i>p</i> -value
Isolated oligohydramnios	1.203	1.022-1.417	0.027
Gestational age (weeks)	0.911	0.897-0.924	<0.001
Maternal age at birth	0.997	0.992-1.002	0.215
Labor induction	1.258	1.184–1.337	<0.001

Adj. HR, adjusted hazards ratio.




Fig. 1. Survival curve demonstrating the cumulative incidence of neurological hospitalization in the offspring to pregnancies complicated by isolated oligohydramnios and normal amniotic fluid volume. *Log-rank (Mantel-Cox) p = 0.001.

Discussion

The impact of oligohydramnios with no known underlying pathology on long-term outcomes of offspring remains uncertain. Most of the previously reported evidence refers to perinatal short-term consequences, and little evidence is proposed regarding any potential long-term impact this exposure may bare on offspring. The main finding of the study is a confirmation of an independent association between pregnancies complicated with IO and long-term neurological-related hospitalizations of the offspring, as compared with unexposed offspring.

The specific neurological diagnoses found significantly more often in the IO group were PDD, movement disorders (including epilepsy), developmental disorders, and degenerative and demyelization disorders. No difference was found, however, in CP rates between the groups, as opposed to a previous report by Sasahara *et al.*²⁰ The discrepancy may be attributed to the inclusion of preterm births only in Sasahara's report. In that report, the study group comprised of deliveries between 22 and 33 weeks of gestation, while an independent risk factor for long-term unfavorable neurological outcome.^{24,25} The current study did not exclude preterm births, though as shown in Table 1 the incidence of preterm births, though as not significantly different to that with normal AFV, 0.8% and 0.6% in the exposed and unexposed groups, respectively. Interaction effect between

preterm births and IO showed an association between IO and CP only in the presence of preterm births, and for this reason, this association was not found in our study.

The association between long-term neurological morbidity and IO may have several possible underlying causes. The first is related to the role of amniotic fluid in fetal development. It is well established that the amniotic fluid is important for fetal growth and protection, both for cushioning and for immunity.¹¹ In fact, the effects of scant space and mechanical pressure in utero caused by decreased amniotic fluid on limb or lung development are discussed widely in both animal models and humans.^{19,26–29} We suggest that an abnormal uterine environment in which the fetus grows exposed to decreased volume of amniotic fluid and limited space may also cause subsequent neurodevelopmental abnormalities.³⁰ This insufficient space may affect neurodevelopment in utero, directly or indirectly, and manifest only later in childhood.

A second pathophysiologic explanation for the association between IO and long-term neurologic morbidity relates to the etiology of IO, believed to arise from decreased placental perfusion and hypoxemia, leading to diminished generation of fetal urine.¹¹ This mechanism may provide another evidence for a stressful fetal environment, granted diminished perfusion. The lack of oxygen and blood flow redistribution is thought to have a negative effect on fetal development, and particularly the nervous system.³¹

SUMC is a sole tertiary medical center serving the entire population of the Negev region in Israel, providing both maternity and pediatric services and hospitalizations. This enables long-term follow-up of major health issues of the offspring and little loss to follow-up. Together with the large cohort size, these are the current study's significant advantages. Several limitations to the study should also be acknowledged with the main limitation being its retrospective nature. As such, this study cannot suggest causation, but only association between IO and long-term neurological complications in the offspring. Moreover, several variables that may have potential significance such as parental neurological illness and other environmental or social factors in the life of the affected offspring cannot be assessed. In addition, the dataset included only neurological-related hospitalizations and lacks cases of ambulatory care or diagnoses that did not require hospitalizations during the disease course and treatment. This limitation may further explain the difference between CP prevalence in a previous study²⁰ and the current study. There may be a degree of underdiagnosis in our study, since many CP cases do not require hospitalization and the question of a selection bias may evoke. The inclusion of hospitalized patients to the current study may evoke the question of a selection bias. While there is a possible selection bias, it would be non-differential and not dependent on the exposure. Therefore, our results maybe an underestimation of the true association. Finally, the study was based on defining oligohydramnios as Amniotic Fluid Index (AFI) of less than 5 cm, a system widely used, though there is some debate concerning the best way to assess AFV as part of fetal examination.^{32–34} And within medical records limitations, we were unable to quantify the AFV from which an impairment is expected.

In conclusion, we report an association between pregnancies complicated by IO and neurological-related hospitalizations of the offspring. Further studies are essential to establish this finding and better understand the association. Only prospective studies will answer the question of causation, thereby suggesting methods of valuable interventions. Supplementary materials. For supplementary material for this article, please visit https://doi.org/10.1017/S2040174419000795

Acknowledgments. None.

Financial support. This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

Avital Dorot wrote the first draft of the manuscript. No honorarium, grant, or other form of payment was given to anyone to produce the manuscript.

Conflict of interest. None.

Ethical standards. This study was conducted as part of the requirements for MD degree from the Goldman Medical School at the Faculty of Health Sciences, Ben-Gurion University of the Negev.

References

- Rossi AC, Prefumo F. Perinatal outcomes of isolated oligohydramnios at term and post-term pregnancy: a systematic review of literature with meta-analysis. *Eur J Obstet Gynecol Reprod Biol.* 2013; 169(2), 149–154.
- 2. Apel-Sarid L, Levy A, Holcberg G, Sheiner E. Placental pathologies associated with intra-uterine fetal growth restriction complicated with and without oligohydramnios. *Arch Gynecol Obstet.* 2009; 280(4), 549–552.
- 3. Guron G, Friberg P. An intact rennin-angiotensin system is a prerequisite for normal renal development. *J Hypertens.* 2000; 18(2), 123–137.
- Pryde PG, Sedman AB, Nugent CE, Barr M, Jr. Angiotensinconverting enzyme inhibitor fetopathy. J Am Soc Nephrol. 1993; 3(9), 1575–1582.
- Fanos V, Marcialis MA, Bassareo PP, et al. Renal safety of Non Steroidal Anti Inflammatory Drugs (NSAIDs) in the pharmacologic treatment of patent ductus arteriosus. J Matern Fetal Neonatal Med. 2011; 24(Suppl 1), 50–52.
- 6. Abou-Ghannam G, Usta IM, Nassar AH. Indomethacin in pregnancy: applications and safety. *Am J Perinatol.* 2012; 29(3), 175–186.
- 7. Moore TR. Amniotic fluid dynamics reflect fetal and maternal health and disease. *Obstet Gynecol.* 2010; 116(3), 759–765.
- Feldman I, Friger M, Wiznitzer A, Mazor M, Holcberg G, Sheiner E. Is oligohydramnios more common during the summer season? *Arch Gynecol Obstet.* 2009; 280(1), 3–6.
- 9. Harman CR. Amniotic fluid abnormalities. Semin Perinatol. 2008; 32(4), 288–294.
- Gizzo S, Noventa M, Vitagliano A, et al. An update on maternal hydration strategies for amniotic fluid improvement in isolated oligohydramnios and normohydramnios: evidence from a systematic review of literature and meta-analysis. *PloS One*. 2015; 10(12), e0144334.
- Underwood MA, Gilbert WM, Sherman MP. Amniotic fluid: not just fetal urine anymore. J Perinatol. 2005; 25(5), 341–348.
- Magann EF, Chauhan SP, Kinsella MJ, McNamara MF, Whitworth NS, Morrison JC. Antenatal testing among 1001 patients at high risk: the role of ultrasonographic estimate of amniotic fluid volume. *Am J Obstet Gynecol.* 1999; 180(6 Pt 1), 1330–1336.
- Zhang J, Troendle J, Meikle S, Klebanoff MA, Rayburn WF. Isolated oligohydramnios is not associated with adverse perinatal outcomes. *BJOG*. 2004; 111(3), 220–225.
- Ott WJ. Reevaluation of the relationship between amniotic fluid volume and perinatal outcome. *Am J Obstet Gynecol.* 2005; 192(6), 1803–1809.

- Hsieh TT, Hung TH, Chen KC, Hsieh CC, Lo LM, Chiu TH. Perinatal outcome of oligohydramnios without associated premature rupture of membranes and fetal anomalies. *Gynecol Obstet Invest.* 1998; 45(4), 232–236.
- Leibovitch L, Kuint J, Rosenfeld E, Schushan-Eisen I, Weissmann-Brenner A, Maayan-Metzger A. Short-term outcome among term singleton infants with intrapartum oligohydramnios. *Acta Paediatr.* 2012; 101(7), 727–730.
- Shrem G, Nagawkar SS, Hallak M, Walfisch A. Isolated oligohydramnios at term as an indication for labor induction: a systematic review and metaanalysis. *Fetal Diagn Ther.* 2016; 40(3), 161–173.
- Rabie N, Magann E, Steelman S, Ounpraseuth S. Oligohydramnios in complicated and uncomplicated pregnancy: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2017; 49(4), 442–449.
- Chien LN, Chiou HY, Wang CW, Yeh TF, Chen CM. Oligohydramnios increases the risk of respiratory hospitalization in childhood: a population-based study. *Pediatr Res.* 2014; 75(4), 576–581.
- Sasahara J, Ishii K, Umehara N, et al. Significance of oligohydramnios in preterm small-for-gestational-age infants for outcome at 18 months of age. J Obstet Gynaecol Res. 2016; 42(11), 1451–1456.
- 21. Godfrey KM, Barker DJ. Fetal programming and adult health. *Public Health Nutr.* 2001; 4(2B), 611–624.
- Barker DJ. The origins of the developmental origins theory. J Intern Med. 2007; 261(5), 412–417.
- Wallack L, Thornburg K. Developmental origins, epigenetics, and equity: moving upstream. *Matern Child Health J.* 2016; 20(5), 935–940.
- Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. N Engl J Med. 2008; 359(3), 262–273.
- 25. Raju TN, Pemberton VL, Saigal S, *et al.* Long-term healthcare outcomes of preterm birth: an executive summary of a conference sponsored by the national institutes of health. *J Pediatr.* 2016; 181, 309–318.e1.
- Wu CS, Chen CM, Chou HC. Pulmonary hypoplasia induced by oligohydramnios: findings from animal models and a population-based study. *Pediatr Neonatol.* 2017; 58(1), 3–7.
- Husain AN, Hessel RG. Neonatal pulmonary hypoplasia: an autopsy study of 25 cases. *Pediatr Pathol.* 1993; 13(4), 475–484.
- Houben JJ. Immediate and delayed effects of oligohydramnios on limb development in the rat: chronology and specificity. *Teratology*. 1984; 30(3), 403–411.
- Christianson C, Huff D, McPherson E. Limb deformations in oligohydramnios sequence: effects of gestational age and duration of oligohydramnios. *Am J Med Genet.* 1999; 86(5), 430–433.
- Roberts D, Nwosu EC, Walkinshaw SA. The fetal outcome in pregnancies with isolated reduced amniotic fluid volume in the third trimester. *J Perinat Med.* 1998; 26(5), 390–395.
- Altshuler G. Some placental considerations related to neurodevelopmental and other disorders. J Child Neurol. 1993; 8(1), 78–94.
- Nabhan AF, Abdelmoula YA. Amniotic fluid index versus single deepest vertical pocket: a meta-analysis of randomized controlled trials. *Int J Gynaecol Obstet.* 2009; 104(3), 184–188.
- Rosati P, Guariglia L, Cavaliere AF, *et al.* A comparison between amniotic fluid index and the single deepest vertical pocket technique in predicting adverse outcome in prolonged pregnancy. *J Prenat Med.* 2015; 9(1–2), 12–15.
- 34. Chauhan SP, Sanderson M, Hendrix NW, Magann EF, Devoe LD. Perinatal outcome and amniotic fluid index in the antepartum and intrapartum periods: a meta-analysis. *Am J Obstet Gynecol.* 1999; 181(6), 1473–1478.